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VaccineDespite decades of vaccination, surveillance, and biosecurity measures, H5N2 low pathogenicity avian
influenza (LPAI) virus infections continue in Mexico and neighboring countries. One explanation for
tenacity of H5N2 LPAI in Mexico is the antigenic divergence of circulating field viruses compared to
licensed vaccines due to antigenic drift. Our phylogenetic analysis indicates that the H5N2 LPAI viruses
circulating in Mexico and neighboring countries since 1994 have undergone antigenic drift away from
vaccine seed strains. Here we evaluated the efficacy of a new recombinant fowlpox virus vector contain-
ing an updated H5 insert (rFPV-H5/2016), more relevant to the current strains circulating in Mexico. We
tested the vaccine efficacy against a closely related subcluster 4 Mexican H5N2 LPAI (2010 H5/LP) virus
and the historic H5N2 HPAI (1995 H5/HP) virus in White Leghorn chickens. The rFPV-H5/2016 vaccine
provided hemagglutinin inhibition (HI) titers pre-challenge against viral antigens from both challenge
viruses in almost 100% of the immunized birds, with no differences in number of birds seroconverting
or HI titers among all tested doses (1.5, 2.0, and 3.1 log10 mean tissue culture infectious doses/bird).
The vaccine conferred 100% clinical protection and a significant decrease in oral and cloacal virus shed-
ding from 1995 H5/HP virus challenged birds when compared to the sham controls at all tested doses.
Virus shedding titers from vaccinated 2010 H5/LP virus challenged birds significantly decreased com-
pared to sham birds especially at earlier time points. Our results confirm the efficacy of the new rFPV-
H5/2016 against antigenic drift of LPAI virus in Mexico and suggest that this vaccine would be a good can-
didate, likely as a primer in a prime-boost vaccination program.
Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).AI, avian
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The use of avian influenza (AI) vaccines for control of high
pathogenicity avian influenza (HPAI) was first reported in 1995
in Mexico during the H5N2 HPAI epizootic [1]. Vaccination
together with other control measures were associated with the
eradication of the H5N2 HPAI virus by mid-1995, but the predeces-
sor H5N2 low pathogenicity avian influenza (LPAI) virus has con-
tinued to circulate in Mexico and spread to some Central
American countries [2,3]. Enzootic H5N2 LPAI infections of poultry
in Mexico and Central America cause a significant financial burden
on poultry production and are still controlled by routine vaccina-
tion and secondary pathogen management control programs [4].
Despite decades of vaccination, surveillance, and biosecurity
measures, H5N2 LPAI is enzootic in large geographic areas of
Mexico and neighboring countries [5–7]. One explanation for
tenacity of H5N2 LPAI is antigenic drift of circulating viruses com-
pared to vaccine seed strains [8,9]. Since 1994, inactivated vac-
cine seed strains have been changed twice because of antigenic
drift of field viruses and loss of vaccine protection. Initially in
1994, an inactivated oil-emulsified AI vaccine using the officially
authorized vaccine seed strain A/chicken/Mexico/CPA-232/1994
(H5N2) provided protection in chickens against the 1995 HPAI
field virus and the early H5N2 LPAI field viruses [1,9,10]. How-
ever, the 1994 vaccine strain was no longer protective against
two later lineages of H5N2 LPAI viruses [9] and, starting in
2009, it was replaced by A/chicken/Mexico/VacunaCPA/2005
(H5N2) [11]. Recently, A/chicken/Mexico/VacunaCPA/2005
(H5N2) has been replaced by A/chicken/Guanajuato/CPA-20966-
15-VS/2015 (H5N2) vaccine seed strain [11]. In addition to inac-
tivated vaccines, H5 recombinant vectors have been used since
1998 [1,12]: recombinant fowlpox virus (FPV) (rFPV) with H5
insert of A/turkey/Ireland/1378/1983 (rFPV-H5/1983), recombi-
nant Newcastle disease with H5 insert of A/chicken/Mex-
ico/435/2005, and recombinant herpesvirus turkey (HVT) with
H5 insert of clade 2.2 A/swan/Hungary/4999/2006 [11]. These
recombinant vectors are used in 1-day-old chicks in the hatchery
[6] to induce earlier protection than can be achieved by inacti-
vated vaccines typically given at 10–14 days of age. However,
for synergism, the live vectored vaccines can be used as a priming
vaccine followed by a boost with inactivated vaccine in the field
[1,11,12].
The continuing antigenic drift of H5N2 LPAI virus in
H5-vaccinated farms [8,9] suggests need for proactive develop-
ment of an updated H5 insert for current and future use. The objec-
tive of this study was to evaluate the efficacy of an experimental
rFPV-H5 vaccine containing an updated H5 insert, more closely
related to the current strains circulating in Mexico, and to provide
experimental protection against a closely related H5N2 subcluster
4 LPAI virus and the regulatory-required 1995 H5N2 HPAI virus.2. Materials and methods
2.1. Vaccine and viruses
A construct of live rFPV vaccine containing an H5 LPAI virus
gene insert from the A/chicken/Mexico/P-14/2016 (GenBank acces-
sion number MF280172) (rFPV-H5 3006, hereafter rFPV-H5/2016)
was constructed the same way as the licensed rFPV-H5/1983
(TROVAC-H, Boehringer Ingelheim Animal Health USA Inc. [BIAH],
Athens, GA, USA) and tested in this experiment. The FPV vector for
rFPV-H5/1983 was derived from the vaccine strain contained in the
DIFTOSEC FPV vaccine (BIAH). The rFPV-H5/1983 received license
in the United States in 1998 and has since been used commercially
in Mexico, Guatemala, El Salvador, and Vietnam [6].The rFPV-H5/2016 vaccine was characterized via immunofluo-
rescence antibody (IFA) assay, polymerase chain reaction (PCR),
and sequencing as described below. For IFA, chicken embryo
fibroblasts (CEF) were infected with rFPV-H5/2016 at a multiplicity
of infection (MOI) of 0.1 or 0.01. Uninfected CEF were included as a
negative control. After 40-hour incubation, the media was removed
and CEF were fixed with 95% ice cold acetone and washed once
with deionized water. The fixed CEF monolayer was incubated
with chicken anti-H5N2 (Charles River, Norwich, CT, USA) as pri-
mary antibody diluted 1:300 in phosphate buffered saline (PBS)
for 1 h at 37 C. The CEF were washed three times with PBS before
incubation with rabbit anti-chicken IgG-FITC (Sigma Aldrich, St
Louis, MO, USA) as secondary antibody diluted 1:500 in PBS for
1 h at 37 C. The CEF were washed three times with PBS. Cultures
were examined for hemagglutinin (HA) expression using fluores-
cent microscopy.
The PCR was performed to ensure both the absence of parental
virus within rFPV-H5/2016 and the presence of the expression
cassette within the targeted recombination region. Platinum PCR
SuperMix High Fidelity (Thermo Scientific, Waltham, MA, USA)
was used for all reactions. In the first PCR, primers Fowlpox probe F
(50 AATATCCGGTCTTAAAGAAGTCGCGG 30) and Fowlpox probe R
(50 TTCCATAGAGGATCATGAGTTTCCGC 30) were used to confirm
the absence of any parental virus in the purified recombinantmate-
rial. These primers bind to a region of the FPV genome which is
deleted during recombination and, as such, only amplify parental
virus. The amplicon produced by parental virus is 819 base pairs in
size. The thermal profile for this reaction was as follows: denatura-
tion at 94 C for 2 min; 35 cycles at 94 C for 30 sec, 56 C for
30 sec, 68 C for 1 min; elongation at 68 C for 5 min; 4 C hold. In
the second PCR, primers 11339CXL (50 GTAGTGATCAAAATACA-
GAACCAT 30) and 11340CXL (50 GAATCCGTCATTCAACTTTCTAGT 30)
were used to amplify the entire expression cassette. These primers
lie just outside of the recombination arm. Although they amplify
both recombinant and wild type FPV, the amplicon produced differ
in size: 4989 base pairs for rFPV-H5/2016 and 4457 base pairs for
parental virus. The thermal profile for this reaction was as follows:
denaturation at 94 C for 2 min; 35 cycles at 94 C for 30 sec,
49.5 C for 30 sec, 68 C for 5 min; elongation at 68 C for 10 min;
4 C hold. The PCR products were examined using 1% agarose gel
electrophoresis.
Finally, the recombination region of rFPV-H5/2016 was
sequenced to confirm that its integrity had been maintained
throughout the purification and scale up process. Primers
11339CXL and 11340CXL were again used to amplify the expres-
sion cassette which was sequenced by Eurofins Genomics (Louis-
ville, KY, USA). The candidate vaccine rFPV-H5/2016 was
administered at 1 day of age by the subcutaneous route at the tar-
get doses of 1.5, 2.0, and 3.1 log10 mean tissue culture infectious
doses (TCID50) in 0.2 ml per bird.
The influenza A isolates A/chicken/Aguascalientes/IA13/11/
2010 H5N2 LPAI virus (2010 H5/LP) (GenBank accession numbers
KM657856 to KM657863) and A/chicken/Queretaro/14588-19/19
95 H5N2 HPAI virus (1995 H5/HP) (GenBank accession numbers
AB558474 and CY015097 to CY015103) were used as challenge
viruses. The 2010 H5/LP virus was chosen because of the epidemi-
ological relevance of LPAI viruses in broiler premises in Mexico,
which currently account for the majority of H5N2 LPAI cases in
broilers and broiler breeders [2,3]. The 1995 H5/HP virus was cho-
sen because it is the mandatory reference isolate for testing and
licensing H5 influenza vaccines by the Mexican veterinary author-
ities. Working stocks were prepared and titrated in embryonated
chicken eggs (ECE) using standard methods [13]. Stocks were
diluted to the target dose with brain heart infusion (BHI) broth
(Becton, Dickinson and Company, Sparks, MD, USA) with penicillin
(2000 units/ml; Sigma Aldrich), gentamicin (200 ug/ml; Sigma
Table 1
Experimental design.
Group N rFPV-H5/2016 vaccine dose (log10 TCID50)1 Challenge virus2
1 20 Sham-vaccinated 2010 H5/LP
2 20 Low dose (1.5) 2010 H5/LP
1528 K. Bertran et al. / Vaccine 38 (2020) 1526–1534Aldrich) and amphotericin B (5 ug/ml; Sigma Aldrich). The
studies were performed in biosafety level 3 enhanced (BSL-3E)
facilities in accordance with procedures approved by the U.S.
National Poultry Research Center (USNPRC) Institutional
Biosecurity Committee.3 20 Medium dose (2.0) 2010 H5/LP
4 20 High dose (3.1) 2010 H5/LP
5 30 Sham-vaccinated 1995 H5/HP
6 30 Low dose (1.5) 1995 H5/HP
7 30 Medium dose (2.0) 1995 H5/HP
8 30 High dose (3.1) 1995 H5/HP
1 The rFPV-H5/2016 vaccine was administered at 1 day old by the subcutaneous
route at the indicated target doses in 0.2 ml per bird.
2 Challenge viruses were A/chicken/Aguascalientes/IA13/11/2010 H5N2 LPAI
virus (2010 H5/LP) and A/chicken/Queretaro/14588-19/1995 H5N2 HPAI virus
(1995 H5/HP).2.2. HA sequence analysis
A total of 125 H5 HA sequences (nucleotide sequence
length > 900) originated from Mexico and other Central American
countries were downloaded from the National Center for Biotech-
nology Information Influenza Virus Resource database in May 2019
and added to sequence alignments. Retrieved sequences were
aligned with other strains used in this study (n = 3) using Multiple
Alignment with Fast Fourier Transformation in Geneious v8.1.2
program and trimmed to remove nucleotides that were outside
the HA1 coding region. Phylogenetic relationships of 128
sequences were inferred from maximum-likelihood (ML) phy-
logeny with RAxML [14] using the general time reversible nucleo-
tide substitution model and visualized with MEGA 7 software.
Bootstrap support values were generated using 1,000 rapid boot-
strap replicates and shown next to the branches (>70). Bayesian
relaxed clock phylogenetic analysis of HA1 region was done using
BEAST v1.8.4 [38]. We applied an uncorrelated lognormal distribu-
tion relaxed clock method, the Hasegawa-Kishino-Yano nucleotide
substitution model, and the Bayesian skyride coalescent prior. A
Markov Chain Monte Carlo method to sample trees and evolution-
ary parameters was run for 30 million generations. At least three
independent chains were combined to ensure adequate sampling
of the posterior distribution of trees (effective sampling size>200).
BEAST output was analyzed with TRACER v1.7.1 with 10% burn-in.
A maximum clade credibility tree was generated for each data set
using TreeAnnotator in BEAST. FigTree 1.4.4 (http://tree.bio.ed.ac.
uk/) was used for visualization of trees. The nucleotide and amino
acid sequence identities between complete HA sequences of vac-
cine and challenge strains were calculated using Geneious v8.1.2
program.
The molecular characterization of H5 HA of the experimental
vaccine (rFPV-H5/2016) and the challenge LPAI (2010 H5/LP) and
HPAI (1995 H5/HP) viruses was performed as described below.
Briefly, the HA sequences were aligned, and residues analyzed in
the Lasergene 12 using Clustal W, MegAlign software (DNA STAR,
Madison, WI, USA). After sequence alignment, the HA antigenic
sites were identified as previously published [15,16]. The potential
N-glycosylation sites were predicted using NetNGlyc server 1.0
(http://www.cbs.dtu.dk/services/NetNGlyc). The HA results were
numbered according to the H5 subtype conversion obtained in
the Influenza Research Database (https://www.fludb.org).2.3. Animals and housing
Two hundred specific pathogen free (SPF) White Leghorn
chickens (BIAH) were randomized into groups (Table 1). For the
vaccination period, each group was housed separately in negative
pressured HEPA-filtered isolators within the animal biosafety
level 2 (ABSL-2) facilities of BIAH. For the challenge period, the
birds were transferred to negative pressured HEPA-filtered
isolators within the animal biosafety level 3 enhanced (ABSL-3E)
facilities of the USNPRC and allowed to acclimate for 3 days
before challenge. Birds had ad libitum access to feed and water
throughout the experiment. This study was reviewed and
approved by the USNPRC Institutional Animal Care and Use
committee.2.4. Experimental design and sampling
Day-old chickens were either vaccinated with rFPV-H5/2016
vaccine at various doses or sham-vaccinated with sterile HVT vac-
cine diluent (BIAH) only (Table 1). Three weeks post-vaccination
(21 days of age), all birds were challenged by the intra-choanal
route with estimated 6 log10 EID50/0.1 ml of either 2010 H5/LP or
1995 H5/HP. The inoculum titers were subsequently verified as
5.9 and 5.7 log10 EID50, respectively, by back titration in ECE. All
the birds were monitored daily for clinical signs and mortality
for 2 weeks following challenge. Severely sick birds were eutha-
nized and counted as dead for the next day in mean death time
(MDT) calculations. Oropharyngeal (OP) and cloacal (CL) swabs
were collected at 2, 4, and 7 days post-challenge (dpc) from 2010
H5/LP challenged groups, and at 2 dpc from 1995 H5/HP
challenged groups and placed in 1.5 ml of BHI with antibiotics
and antifungal. Serum samples were collected pre-challenge
(18 days post-vaccination) and at termination (14 dpc). At 14
dpc, surviving birds were euthanized by cervical dislocation.
2.5. Determination of virus from swabs
Swab samples in BHI were processed for quantitative real-time
reverse transcriptase PCR (qRRT-PCR) [17] with modifications [18]
to determine viral RNA titers. The standard curves for viral RNA
quantification were established with RNA extracted from dilutions
of the same titrated stocks of the challenge virus. This is a standard
protocol among published veterinary influenza vaccine studies
given the high correlation between the quantity of RNA deter-
mined by qRRT-PCR and the EID50 determined by ECE titration
when the same challenge virus stock is used to generate the
standard curve [19]. The limit of detection was 1.9 log10 EID50/ml
for 2010 H5/LP and 1.5 log10 EID50/ml for 1995 H5/HP.
2.6. Serology
Hemagglutinin inhibition (HI) assays were performed using H5
antigens specific for each corresponding challenge antigen. The
antigens were prepared as previously described [20] and the HI
assays were performed according to standard procedures [21].
Titers were expressed as log2 geometrical mean titers (GMT).
GMT included only positive serum samples. Samples with titers
below 3 log2 GMT were considered negative and then assigned as
2 log2 GMT for statistical purposes.
2.7. Statistical analysis
Statistical analyses were performed using Prism 7 (GraphPad
software, San Diego, CA, USA). Survival curves were compared
K. Bertran et al. / Vaccine 38 (2020) 1526–1534 1529using the Mantel-Cox Log-rank test. Fisher’s exact test was used to
analyze statistical significance of virus shedding. Mean virus
shedding titers and HI antibody titers had a non-parametric
distribution and were analyzed with Kruskal–Wallis test and
Dunn’s Multiple Comparison test. A P-value of < 0.05 was consid-
ered to be significant. P values in figures are represented as: * for
p < 0.05; ** for p < 0.01; *** for p < 0.001; and **** for p < 0.0001.3. Results
3.1. Characterization of rFPV-H5/2016
Expression of HA, PCR purity, and sequencing of rFPV-H5/2016
were confirmed. The anti-H5N2 polyclonal antibody reacted
strongly with rFPV-H5/2016, while no binding was detected in
the uninfected control (Fig. S1). The PCR specific to non-
recombinant FPV confirmed the absence of parental virus within
rFPV-H5/2016 (Fig. S2a). The PCR binding to the recombination
arms of rFPV-H5/2016 confirmed the presence of a single band of
the expected size (Fig. S2b). Sequencing of this amplicon confirmed
the intended sequence for recombination arms, promoter, and
gene (data not shown).
3.2. HA sequence analysis
To understand the role of HA in the protection of chickens
against challenge with Mexican H5N2 LPAI and HPAI viruses, we
compared the amino acid and nucleotide identity for complete
HA, the HA antigenic sites, and the predicted N-glycosylation sites
between the experimental rFPV-H5/2016 vaccine seed strain and
the challenge strains.
The HA sequences of the experimental rFPV-H5/2016 vaccine
seed strain (A/chicken/Mexico/P-14/2016), the two experimental
challenge viruses (A/chicken/Aguascalientes/IA13/11/2010 and
A/chicken/Queretaro/14588–19/1995), and the 5 vaccine seed
strains used in Mexico from 1995 to 2017 were compared with
each other and with other Mexican and Central American HA
sequences (Table 2, Fig. 1, and S3). The Mexican and Central
American HA sequences formed a well-supported monophyletic
group with four distinct phylogenetic subclusters defined by high
posterior probabilities in Bayesian phylogeny (>95) and bootstrap
values in ML phylogeny (>80) (Fig. 1). The vaccine seed strain
A/chicken/Mexico/CPA-232/1994 and the 1995 H5/HP isolate
belonged to subcluster 3, while the experimental rFPV-H5/2016
vaccine seed strain, A/chicken/Mexico/VacunaCPA/2005,
A/chicken/Mexico/435/2005, and the 2010 H5/LP isolate belonged
to subcluster 4. The HA sequences of the rFPV-H5/2016 vaccineTable 2
Nucleotide and amino acid full-length HA sequence similarities among vaccine and challe
Nucleotide sequence id
Virus strain Ire/83 Hungary
A/turkey/Ireland/1378/1983 – vax – 87.2
A/mute_swan/Hungary/4999/2006 – vax 90.1 –
A/chicken/Mexico/CPA-232/1994 – vax* 87.6 87.0
A/chicken/Mexico/435/2005 – vax 83.9 83.1
A/chicken/Mexico/VacunaCPA/2005 – vax 83.6 82.4
A/chicken/Mexico/P-14/2016 – exp vax 82.7 82.0
A/chicken/Queretaro/14588–19/1995 – 1995 H5/HP 88.7 87.5
A/chicken/Aguascalientes/IA13/11/2010 – 2010 H5/LP 82.2 81.0
Amino acid sequence id
Vax, vaccine seed strains; exp vax, experimental vaccine seed strain tested here; 1995
strain.
* The full-length HA gene of A/chicken/Hidalgo/28159-232/1994(H5N2) virus was useseed strain and the 2010 H5/LP isolate clustered together phyloge-
netically (Fig. 1 and S3). The A/turkey/Ireland/1378/1983 and
A/mute_swan/Hungary/4999/2006 vaccine seed strains belonged
to a different genetic lineage (the latter was not included in the
trees due to its large phylogenetic distance with Mexican and
Central American HA sequences) (Fig. 1 and S3) and shared the
lowest (82.2%) full-length HA sequence identities with the 2010
H5/LP challenge virus (Table 2). In contrast, the HA sequence of
the experimental rFPV-H5/2016 vaccine seed strain had 96.3%
amino acid and nucleotide sequence identities with the 2010
H5/LP isolate (Table 2), and 88.7% (amino acid) and 89.2% (nucleo-
tide) sequence identity with the 1995 H5/HP isolate (Table 2). The
HA sequence of the other 3 vaccine seed strains (A/chicken/Mex
ico/CPA-232/1994, A/chicken/Mexico/435/2005, and A/chicken/M
exico/VacunaCPA/2005) had 88.3–94.0% sequence identities with
the 2010 H5/LP isolate (Table 2).
Both the amino acid alignment and the analysis of the antigenic
sites showed a few amino acid differences between the HA
sequence of the experimental vaccine strain and the challenge
strains (data not shown). Some of these amino acid substitutions
resulted in potential new predicted glycosylation sites in the
experimental rFPV-H5/2016 vaccine seed strain and the 2010 H5/
LP strain, which were not detected in the 1995 H5/HP strain (data
not shown). In particular, these two more recent strains, i.e. the
experimental vaccine strain and the 2010 H5/LP virus, obtained
additional potential glycosylation sites in positions 84, 126, and
163 of the HA, which are found within antigenic sites A, D, and E,
respectively.3.3. Efficacy of rFPV-H5/2016 on protection against 2010 H5/LP virus
Clinical protection. All birds survived 2010 H5/LP challenge,
except for one sham-vaccinated bird that died at 7 dpc from
unrelated causes and was excluded from the study (Fig. 2a).
Sham-vaccinated and vaccinated birds lacked clinical signs from
rFPV-H5/2016 vaccination or following challenge with 2010
H5/LP virus.
Serology. None of the sham-vaccinated birds had detectable HI
antibody titers before challenge (Fig. 3a). In contrast, 18/20 birds
of each vaccinated group had antibodies detected when using
2010 H5/LP challenge virus as test antigen on serum samples
collected prior to challenge, with GMT ranging 3.4 to 4.2 log2
(Fig. 3a). At termination, 100% of the sham-vaccinated and rFPV-
H5/2016 vaccinated birds had similarly high HI antibody titers.
An anamnestic response was observed after challenge for the
sham-vaccinated group (6.8-fold increase) and all vaccinated
groups (5.4-to-6-fold increase) (Fig. 3a).nge H5 AI isolates.
entity matrix
232 435 VaCPA Mx16 H5/HP H5/LP
81.4 79.2 79.1 79.2 81.9 79.4
79.9 78.0 77.6 77.2 80.1 77.3
– 92.0 91.3 90.3 97.6 90.5
90.8 – 93.6 90.3 91.6 90.8
89.7 94.7 – 90.8 90.9 92.0
88.7 92.0 93.6 – 89.2 96.3
97.5 90.8 89.4 88.7 – 89.5
88.3 92.4 94.0 96.3 88.3 –
entity matrix
H5/HP, H5N2 HPAI virus challenge strain; 2010 H5/LP, H5N2 LPAI virus challenge
d instead, which is found to be similar to A/chicken/Mexico/CPA-232/1994 [9].
Fig. 1. Relaxed clock molecular phylogenetic tree for H5 gene from Mexico and other Central American countries. The phylogenetic relationships have been estimated by
Bayesian molecular clock analysis. The branches colored with blue identify high posterior probabilities >95%. The brackets represent the genetic subclusters supported by
high values of posterior probabilities in Bayesian phylogeny (>95) and bootstrap values in maximum-likelihood phylogeny (>80). The following taxa are highlighted: the 5
vaccine seed strains used in Mexico from 1995 to 2017 (red), the experimental vaccine seed strain (blue), and the challenge viruses 2010 H5/LP (orange) and 1995 H5/HP
(green) used in this study. A/mute_swan/Hungary/4999/2006 was not included due to its large phylogenetic distance with Mexican and Central American HA sequences.
1530 K. Bertran et al. / Vaccine 38 (2020) 1526–1534Viral shedding. All the sham-vaccinated birds (20/20) excreted
high virus titers in the oropharynx at 2 and 4 dpc (mean 5.8 and
5.7 log10 EID50/ml, respectively), but fewer birds (9/20) and lower
titers (2.3 log10 EID50/ml) were shed via the OP route at 7 dpc
(Fig. 4a). Low virus titers (mean 2.2–2.5 log10 EID50/ml) weredetected in the cloaca of 12/20 (2 dpc), 11/20 (4 dpc), and 8/20
(7 dpc) sham-vaccinated birds (Fig. 4b). Mean OP and CL shedding
titers of the three vaccine-dose groups were statistically lower
than those of sham-vaccinated controls at 2 dpc, but number of
birds shedding was significantly different only for CL shedding
Fig. 3. Serology from chickens sham-vaccinated or vaccinated with rFPV-H5/2016 vaccine at various doses and challenged with a. 2010 H5/LP virus or b. 1995 H5/HP virus. HI
titers pre- and post-challenge against corresponding challenge viruses as test antigens. Titers are expressed as log2 GMT. GMT includes only positive serum samples. Samples
with titers below 3 log2 GMT were considered negative. Ratios above the bars indicate the number of birds with HI titers from the total number of birds. P values in the figure
are represented as: * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.
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Fig. 2. Survival curves of chickens vaccinated with rFPV-H5/2016 vaccine at various doses or sham-vaccinated and challenged with a. 2010 H5/LP virus or b. 1995 H5/HP
virus. P values in figures are represented as: * for p < 0.05; ** for p < 0.01; *** for p < 0.001; and **** for p < 0.0001.
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no 1.5 log10 TCID50) had significantly lower OP and CL shedding
titers than sham-vaccinated controls at 4 dpc, and no significant
differences were observed at 7 dpc (Fig. 4a and b). No significant
differences were observed between the three vaccine-dose groups
regarding shedding titers or number of birds shedding at any time
point (Fig. 4a and b).
3.4. Efficacy of rFPV-H5/2016 on protection against 1995 H5/HP virus
Clinical protection. After 1995 H5/HP challenge, 26/30 (87%)
sham-vaccinated birds showed acute severe clinical disease and
death, with a MDT of 3.5 dpc (Fig. 2b). All the vaccinated birds
remained clinically healthy during the observation period (14
dpc), with no clinical signs from the rFPV-H5/2016 vaccination or
following challenge with 1995 H5/HP virus.
Serology. None of the sham-vaccinated birds had detectable HI
antibody titers before challenge (Fig. 3b). In contrast, 23/30 to
29/30 birds of the vaccinated groups had antibodies detected when
using the 1995 H5/HP challenge virus as test antigen on serum
samples collected prior to challenge, with GMT ranging 3.6 to 3.8
log2 (Fig. 3b). At termination, 93–100% of the vaccinated birds
had similarly moderate-to-high HI antibody titers. All vaccinatedgroups had an anamnestic response (2.3–3.6-fold increase) after
challenge (Fig. 3b).
Viral shedding. High virus titers were detected at 2 dpc in
the oropharynx (mean 4.1 log10 EID50/ml) and cloaca (mean 3.4
log10 EID50/ml) of 25/30 and 19/30 sham-vaccinated birds, respec-
tively (Fig. 4c and d). Mean OP and CL shedding titers of vaccinated
birds were statistically lower than those of sham-vaccinated
controls, as well as number of birds shedding (Fig. 4c and d). No
significant differences were observed between vaccine-dose
groups regarding OP and CL shedding titers and number of birds
shedding (Fig. 4c and d).
4. Discussion
After two decades of vaccination and use of other disease con-
trol tools, H5N2 LPAI still affects many farms in Mexico and neigh-
boring countries [5–7]. Antigenic drift of circulating field viruses
away from vaccine strains is the most likely explanation for the
presence of enzootic infections [8,9]. Here we evaluated the
efficacy of experimental rFPV-H5/2016 vaccine containing an
updated H5 insert to provide protection against a recent Mexican
H5N2 LPAI virus from 2010 and the original type strain of H5N2
HPAI virus from 1995.
Fig. 4. Scatter plot of oropharyngeal (OP) and cloacal (CL) shedding from chickens sham-vaccinated or vaccinated with rFPV-H5/2016 vaccine at various doses and challenged
with 2010 H5/LP virus or 1995 H5/HP virus. Shedding titers are expressed as log10 EID50/ml with error bars included. The limit of detection of the qRRT-PCR was 1.9 log10
EID50/ml for 2010 H5/LP and 1.5 log10 EID50/ml for 1995 H5/HP. P values in the figure are represented as: * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.
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ments show the divergence of H5N2 viruses in Mexico into multi-
ple subclusters. However, only a single lineage of virus evolved and
maintained in Mexican poultry, eventually giving rise to subcluster
4. As previously suggested [9], our data indicates that the H5N2
LPAI viruses circulating in Mexico and neighboring countries since
1994 have undergone antigenic drift away from vaccine seed
strains used in this country. Lee et al. (2004) conducted cross-HI
tests with 8 isolates representative of different Mexican H5N2
virus sublineages and found that the viruses belonging to subclus-
ter 2 (A/chicken/Aguascalientes/124-3705/1998 and A/chicken/Pu
ebla/231-5284/1998) and subcluster 4 (A/chicken/Puebla/28159-
474/1995, A/chicken/El_Salvador/102711-1/2001, and A/chicken/
Guatemala/194573/2002) in our phylogenetic tree are antigeni-
cally different from the A/chicken/Mexico/CPA-232/1994 vaccine
strain and from each other [9]. Similarly, Escorcia et al. (2010) per-
formed phylogenetic and serological analysis on H5N2 LPAI field
viruses isolated in Mexico between 1994 and 2008 and revealed
that molecular drift in HA gene follow a yearly trend, suggesting
gradually cumulative sequence mutations [22]. In particular,
sequence similarities to the vaccine strain A/chicken/Mexico/
CPA-232/1994 were 94.5–98% for 1994–1996 isolates, but dropped
to 90–91% for 2006–2008 isolates [22]. Interestingly, the authors
also showed that in HI tests using antiserum produced with anti-
gen A/chicken/Mexico/CPA-232/1994, HI titers were significantly
higher in subcluster 4 viruses isolated in 2002 compared tosubcluster 4 viruses isolated between 2006, 2007, and 2008 [22].
In our study, sequence similarities between A/chicken/Mexico/
CPA-232/1994 and the 1995 H5/HP challenge isolate (subcluster
3) or the 2010 H5/LP challenge isolate (subcluster 4) were <91%
and >97%, respectively, in line with Escorcia et al. (2010) [22].
Our results confirm that H5N2 LPAI viruses have been drifting
away from vaccines used in Mexico, and that some currently used
vaccines may no longer be sufficiently protective against circulat-
ing viruses, which could explain their continuing diagnosis in clin-
ical cases of respiratory disease [5–7]. In addition, the continued
use of inadequate vaccines may have an effect on the evolution
of AI virus [9], which is concerning due to the possibility of muta-
tion again to the HP form of the virus [23–26]. Collectively, our
results confirm the need to update the vaccines used in Mexico.
The H5 insert candidate tested here had very high genetic simi-
larity with the 2010 H5/LP challenge virus, but <90% genetic simi-
larity with the 1995 H5/HP challenge virus, the reference isolate
for vaccine licensing in Mexico. Nonetheless, the tested rFPV-
H5/2016 vaccine provided protective HI titers pre-challenge
against both challenge antigens in almost 100% of the immunized
birds, with no differences in number of birds seroconverting or HI
titers among tested doses. The vaccine conferred clinical protection
against 1995 H5/HP virus challenge, and a significant decrease in
virus shedding on both OP and CL swabs compared to sham controls
at all tested doses. It is worthmentioning that two out of the 4 sham
controls that survived 1995 H5/HP challenge were not infected
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at termination, resulting in 93% infection and mortality rates and
thus complying with the acceptance criteria for vaccine efficacy
studies of 90% mortality in shams [11,27]. The reason why the
rFPV-H5/2016 vaccine conferred protection against 1995 H5/HP
challenge despite these isolates being <90% similar could be that,
although the insert (as well as the 2010 H5/LP virus) had acquired
3 potential N-glycans in antigenic sites A, D, and E that are not
found in the 1995 H5/HP virus, these N-glycans did not physically
block access to antigenic sites in the 1995 H5/HP virus, likely allow-
ing the vaccine-induced antibody-mediated and/or cell-mediated
response to effectively neutralize the virus [28–32].
Virus shedding titers from vaccinated 2010 H5/LP virus chal-
lenged birds significantly decreased compared to sham birds espe-
cially at earlier time points. However, virus titers were still
relatively high and significant virus titer reduction was less likely
over time. Albeit vaccination does not completely prevent virus
replication [2], the shedding of H5 LPAI viruses is of concern
because of the potential for transmission to naïve flocks and the
possibility of mutation to the HP form of the virus [9,23–26].
Eggert et al. (2010) [33] evaluated the efficacy of 10 commercially
available H5 vaccines against challenge with H5N2 LPAI viruses
isolated from Latin America in 2003 [33]. The original 1994 vaccine
seed virus in commercial inactivated vaccines did not significantly
reduce challenge virus shed titers. However, two seed strains of
inactivated vaccines, genetically more closely related to the chal-
lenge virus, did significantly reduce respiratory shedding titers,
but these were still relatively high (4 and 4.4 log10 EID50/ml). In
addition, an rFPV containing a more distantly related Eurasian lin-
eage H5 gene insert significantly reduced respiratory shedding as
compared to shams, but mean titers among shedders were
3.9 log10 EID50/ml [33]. Collectively, these findings indicate that
single vaccinations may not provide optimal immunity capable of
preventing all H5 LPAI virus replication and shedding, but the goal
of vaccination is to reduce virus replication and ultimately reduce
transmission [2]. Therefore, further studies aimed at optimizing
the efficacy of rFPV-H5/2016 are needed, such as increasing the
dose or using it as a priming vaccine in the hatchery followed by
inactivated AI virus vaccine boost in the field.
The choice to update a live virus vector vaccine insert as
opposed to an inactivated whole-virus vaccine responds to the fol-
lowing: (i) vector vaccines allow for rapid insertion of any influ-
enza HA (or other) gene, making them attractive platforms due
to constant antigenic shift and drift among AI viruses [34,35];
and (ii) vector vaccines can stimulate humoral and cellular immu-
nity when given parenterally and, if they replicate at a mucosal
site, induce mucosal immunity, thus reducing shedding [1]. The
mentioned advantages of vector vaccines, together with the
efficacy of the updated rFPV-H5/2016 vaccine tested here against
both 2010 H5/LP and 1995 H5/HP Mexican viruses, suggest this
vaccine would be a good candidate for licensing in Mexico, likely
as a primer at the hatchery followed by an inactivated adjuvanted
vaccine on the farm [36,37].
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